Literature DB >> 7595233

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.

I Hara1, Y Takechi, A N Houghton.   

Abstract

The immune system can recognize differentiation antigens that are selectively expressed on malignant cells and their normal cell counterparts. However, it is uncertain whether immunity to differentiation antigens can effectively lead to tumor rejection. The mouse brown locus protein, gp75 or tyrosinase-related protein 1, is a melanocyte differentiation antigen expressed by melanomas and normal melanocytes. The gp75 antigen is recognized by autoantibodies and autoreactive T cells in persons with melanoma. To model autoimmunity against a melanocyte differentiation antigen, mouse antibodies against gp75 were passively transferred into tumor-bearing mice. Passive immunization with a mouse monoclonal antibody against gp75 induced protection and rejection of both subcutaneous tumors and lung metastases in syngeneic C57BL/6 mice, including established tumors. Passive immunity produced coat color alterations but only in regenerating hairs. This system provides a model for autoimmune vitiligo and shows that immune responses to melanocyte differentiation antigens can influence mouse coat color. Immune recognition of a melanocyte differentiation antigen can reject tumors, providing a basis for targeting tissue autoantigens expressed on cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595233      PMCID: PMC2192219          DOI: 10.1084/jem.182.5.1609

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serum.

Authors:  J P Klerx; C J Beukelman; H Van Dijk; J M Willers
Journal:  J Immunol Methods       Date:  1983-10-14       Impact factor: 2.303

2.  Vitiligo in patients with metastatic melanoma: a good prognostic sign.

Authors:  J J Nordlund; J M Kirkwood; B M Forget; G Milton; D M Albert; A B Lerner
Journal:  J Am Acad Dermatol       Date:  1983-11       Impact factor: 11.527

3.  Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice.

Authors:  S Welt; M J Mattes; R Grando; T M Thomson; R W Leonard; P B Zanzonico; R E Bigler; S Yeh; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

4.  IFN-treatment of B16-F1 versus B16-F10: relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread.

Authors:  M Zöller
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

5.  The role of tyrosinase in autoimmune vitiligo.

Authors:  Y H Song; E Connor; Y Li; B Zorovich; P Balducci; N Maclaren
Journal:  Lancet       Date:  1994-10-15       Impact factor: 79.321

6.  Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies.

Authors:  T M Thomson; F X Real; S Murakami; C Cordon-Cardo; L J Old; A N Houghton
Journal:  J Invest Dermatol       Date:  1988-04       Impact factor: 8.551

7.  Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.

Authors:  A N Houghton; M Eisinger; A P Albino; J G Cairncross; L J Old
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

8.  Antibodies to normal human melanocytes in vitiligo.

Authors:  G K Naughton; M Eisinger; J C Bystryn
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

9.  Human melanoma antigen AH is an autoantigenic ganglioside related to GD2.

Authors:  T Watanabe; C S Pukel; H Takeyama; K O Lloyd; H Shiku; L T Li; L R Travassos; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

10.  Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

Authors:  R F Wang; P F Robbins; Y Kawakami; X Q Kang; S A Rosenberg
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  60 in total

1.  Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.

Authors:  G Zeng; C E Touloukian; X Wang; N P Restifo; S A Rosenberg; R F Wang
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

2.  Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.

Authors:  Paul F Robbins; Mona El-Gamil; Yong F Li; Gang Zeng; Mark Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

3.  Tumours can act as adjuvants for humoral immunity.

Authors:  D M Brown; T L Fisher; C Wei; J G Frelinger; E M Lord
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

4.  Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.

Authors:  Jack C F Liao; Polly Gregor; Jedd D Wolchok; Francesca Orlandi; Diane Craft; Carrie Leung; Alan N Houghton; Philip J Bergman
Journal:  Cancer Immun       Date:  2006-04-21

5.  Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.

Authors:  Yvonne M Saenger; Yanyun Li; Karoline C Chiou; Brian Chan; Gabrielle Rizzuto; Stephanie L Terzulli; Taha Merghoub; Alan N Houghton; Jedd D Wolchok
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

6.  Mouse model for pre-clinical study of human cancer immunotherapy.

Authors:  Zhiya Ya; Yared Hailemichael; Willem Overwijk; Nicholas P Restifo
Journal:  Curr Protoc Immunol       Date:  2015-02-02

Review 7.  The new vaccines: building viruses that elicit antitumor immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

8.  B16 as a mouse model for human melanoma.

Authors:  W W Overwijk; N P Restifo
Journal:  Curr Protoc Immunol       Date:  2001-05

9.  Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

Authors:  Adam D Cohen; Adi Diab; Miguel-Angel Perales; Jedd D Wolchok; Gabrielle Rizzuto; Taha Merghoub; Deonka Huggins; Cailian Liu; Mary Jo Turk; Nicholas P Restifo; Shimon Sakaguchi; Alan N Houghton
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

10.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.